Niels Jongs

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

David C. Wheeler, Bergur V. Stefánsson, Niels Jongs et al. · The Lancet Diabetes & Endocrinology · 2020 · 530 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson et al. · Kidney International · 2021 · 397 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Niels Jongs, Tom Greene, Glenn M. Chertow et al. · The Lancet Diabetes & Endocrinology · 2021 · 208 citations · Full text

Medicine, Nephrology, Pharmacotherapy +10

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow et al. · The Lancet Diabetes & Endocrinology · 2021 · 194 citations · Full text

Medicine, Nephrology, Pharmacotherapy +15

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

Michele Provenzano, María Jesús Puchades, Carlo Garofalo et al. · Journal of the American Society of Nephrology · 2022 · 176 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16